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This issue of the British Journal of Cancer contains four reports
showing a lack of mutation of Bcl10 in genomic DNA from malig-
nancies of different histological subtypes. These data appear to be
at variance with our original report implicating Bcl10 mutations in
the pathogenesis of a wide range of turnours (Willis et al, 1999).
However, from our further work it now seems that at least some of
the Bcl10 abnormalities, originally described as mutations, in fact
represented post-transcriptional RNA modification of Bcl10 and
are not encoded in genomic DNA.
Bcl10 was cloned through its direct involvement in chromo-
somal translocation t(1;14)(p22;q32), a rare but recurrent translo-
cation of MALT lymphoma (Willis et al, 1999). The presence of an
amino-terminal caspase recruitment domain in Bcl10 suggested a
role in the apoptotic cascade, and from its involvement in the
chromosomal translocation it was anticipated that Bcl10, like
Bcl2, would be anti-apoptotic. However, wild-type Bcl10 is pro-
apoptotic and has the features of a tumour suppressor gene
(Koseki et al, 1999; Thome et al, 1999; Willis et al, 1999; Yan
et al, 1999; Zhang et al, 1999).
We therefore sought Bcl10 mutations first in cDNA clones from
one MALT lymphoma with t(1;14)(p22:q32). These comprised
point mutations, which were often multiple, deletions at the exon
3–4 boundary, and insertions and deletions within two homopoly-
meric runs of eight adenines and seven thymidines. An identical
spectrum of cDNA abnormalities has been detected independently
in other cases of t(1;14)(p22;q32) MALT lymphoma (Zhang et al,
1999), making it unlikely that all these changes represented poly-
merase chain reaction or cloning artefacts. Thus, in MALT
lymphoma with t(1;14)(p22;q32) there were multiple and ongoing
Bcl10 abnormalities. We assumed initially that these reflected the
indolent behaviour of MALT lymphoma and that with further in
vivo selection, a dominant clone would ultimately emerge.
However, we have now sequenced multiple cDNA clones from
various malignant cell lines, primary lymphoid tumours and normal
tissues and found all three types of abnormality at varying frequency
in all instances. The data presented originally (Table 2 in Willis et al,
1999) referred to cDNA clones from six malignant cell lines,
including Tera-1, Tera-2, GCT-44 and from three mesothelioma
lines, and in all, multiple Bcl10 abnormalities were detected. In
contrast, a much lower mutational frequency was detected in
genomic DNA. Also, multiple cDNA abnormalities have been
detected in some cell lines, including the Tera-2 cell line in the pres-
ence of apparently normal germline DNA (Dyer et al, 1999).
To summarize the three types of deviation from the wild-type
sequence:
a. Bcl10 utilizes three alternative splice sites at the exon 3–4
boundary
b. Alterations within the homopolymeric runs of eight As and
seven Ts are common in Bcl10 cDNAs, and in most
instances are not templated
c. Bcl10 point mutations are multiple and ongoing. Whether
all point mutations are present in genomic DNA or whether
some are non-templated is not clear.
Bcl10 therefore appears to undergo what has been termed
‘molecular misreading’ (van Leeuwen et al, 1998) and at least
some of the discrepancies between our initial data and those
reported here can be ascribed to our use of cDNA rather than
genomic DNA.
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